Abbott Laboratories

ABT · NYSE

Abbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.

Follow Add to Watchlist Ask Question

NYSE ABT Coverage Bootstrap Health Care Medical Devices Diagnostics

Latest ReportMay 13, 2026Abbott (ABT): the diabetes-device machine now carrying a $20.6B cancer-diagnostics betView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.